NEW YORK, Feb 13, 2026, 09:32 (ET) — Regular session
- RGC was recently quoted up roughly 7.8% ahead of the bell, building on Thursday’s strong advance.
- Thursday saw the stock whipsaw, though trading volume remained thin compared to its recent norms.
- U.S. inflation numbers are in focus, with investors also weighing the market holiday coming up Monday.
Regencell Bioscience Holdings Limited jumped about 7.8% to $31.29 ahead of the Friday open. On Thursday, shares wrapped up 8.6% higher at $29.02, trading between $25.85 and $30.39, with volume coming in around 193,140. (Investing)
Moves like this have put RGC’s wild price action front and center for short-term traders, often pushing fundamentals to the sidelines. With the stock able to swing by several dollars on relatively light volume, it’s the open that sets the tone — premarket prints barely matter.
Markets are jumpy across the board. U.S. equities kicked off with traders digesting January’s Consumer Price Index (CPI) data, a key inflation read, parsing out any clues for possible rate cuts in the months ahead. “The trend in disinflation continues,” said Michael Metcalfe, State Street’s head of market strategy. (Reuters)
Regencell’s market cap landed near $14.35 billion on Thursday, factoring in about 494.49 million shares outstanding, market data show. Trading volume didn’t reach the three-month average this session. The stock has swung from as low as $0.09 to as high as $83.60 over the past year, underscoring just how volatile the name can be. (Investing)
Hong Kong’s Regencell, trading as RGC on the Nasdaq, describes itself as a bioscience firm working on traditional Chinese medicine (TCM) treatments aimed at attention deficit hyperactivity disorder and autism spectrum disorder. (Reuters)
The company boosted its share count by capitalizing its share premium, handing out 37 new ordinary shares for each one already on the books—a move classified as a 38-for-1 forward stock split under U.S. accounting standards, according to the firm. (SEC)
At the moment, traders are eyeing two main issues: liquidity—will it materialize?—and whether the stock manages to hold above big levels such as $30 after the open. That first hour often delivers the most pain for gapping names.
Rapid swings carry their own mechanical risks. Exchanges have the ability to halt trading in stocks that swing sharply, a volatility brake designed for market order. When the tape runs thin, those pauses often make the stop-and-go rhythm even more pronounced.
Sharp moves higher can just as quickly turn ugly on the way down. If bids dry up, that thin liquidity which fuels rallies also means selling gets tricky—last-in buyers riding the wave may find the exit crowded.
The next test on the calendar isn’t far off. U.S. markets shut down Monday, Feb. 16 for Presidents Day, then reopen on Tuesday, Feb. 17. Traders are eyeing RGC’s recent surge to see if the momentum carries through the holiday break and into the shortened week. (Nasdaq)
